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Neutrophils are not consistently activated by 
antineutrophil cytoplasmic antibodies in vitro
Antineutrophil cytoplasmic antibody (ANCA) vasculitis is char-
acterised by autoantibodies against myeloperoxidase (MPO) and 
proteinase 3 (PR3). The evidence that ANCA are pathogenic comes 
from in vitro studies in which IgG from patients with anti-MPO 
or anti-PR3 antibodies activate neutrophils to undergo respiratory 
burst and degranulation. Furthermore, murine monoclonal anti-
bodies against human MPO and PR3 and a chimeric humanised 
anti-PR3 monoclonal antibody activate neutrophils. The paradigm 
of neutrophil activation by ANCA has therefore become estab-
lished.1 Further support for the pathogenicity of ANCA comes 
from in vivo studies in which injection of anti-MPO antibodies 
causes focal necrotising crescentic glomerulonephritis in mice.2
We assessed the effect of purified ANCA on the activation of 
TNFα primed neutrophils using 10 control IgGs, 11 MPO-ANCA 
and 9 PR3-ANCA using two different assays of the neutrophil 
respiratory burst (full methods are in a online supplementary file 
1). We found no significant difference in two separate neutrophil 
donors (figure 1A-C). We also used assays for four markers of 
neutrophil degranulation and found no differences in two neutro-
phil donors (figure 1D-G). The results are not due to inactivity of 
the purified ANCA IgG preparations. Aliquots of the same ANCA 
and control IgG batches were used in a recent publication where 
we demonstrated clear effects of these ANCA IgG preparations on 
monocytes, in experiments performed with during the same period 
of time.3
Our data challenge the established paradigm of neutrophil 
activation by ANCA. It is not clear why our results differ from 
others, but note that most previous publications have included 
small numbers which might lead to chance effects and selection 
bias. The ability of ANCA to activate neutrophils may be affected 
by affinity. We did not measure affinity or explore this possibility. 
We reviewed the literature to find publications in which six or 
more MPO-ANCA or PR3-ANCA IgG samples were compared 
with a similar number of control IgG samples and found only two. 
Franssen et al compared IgG purified from 17 PR3-ANCA posi-
tive patients, 14 MPO-ANCA positive patients and 16 controls. 
The patients were consecutive, eliminating selection bias.4 
These authors found no significant effect of MPO-ANCA IgG 
on neutrophil respiratory burst using the DHR 123 and ferricy-
tochrome C assays, and no effect on degranulation as measured 
by glucuronidase and lactoferrin release. There was an effect for 
PR3-ANCA which, although statistically significant, was small 
in magnitude. In all cases, the level of activation was much less 
than with N-formylmethionine-leucyl-phenylalanine. Harper et al 
compared 23 MPO-ANCAs, 15 PR3 ANCAs and 8 control IgGs 
using ferricytochrome C, calcium flux and MPO release assays.5 
Both MPO-ANCA and PR3-ANCA caused significant activation 
compared with control IgG. However, in contrast to the study by 
Franssen et al, MPO-ANCA had a greater effect.
A recent report consistent with our data suggests that ANCA 
IgG does not activate neutrophils in vitro.6 Kraaij et al showed 
that serum from patients with ANCA vasculitis induced neutrophil 
extracellular traps (NET) formation, but this was unaffected by 
IgG depletion. In addition, purified IgG was unable to induce NET 
formation. This suggested that factors in the serum of patients with 
vasculitis, other than IgG, could activate neutrophils. This raises 
the possibility that the purity of IgG preparations could have influ-
enced results in previous studies. We emphasise that our data do not 
exclude a role for neutrophils in the pathogenesis of ANCA vascu-
litis. ANCA may have direct or indirect effects on neutrophils in 
vivo that are not evident using in vitro assays of activation. We also 
acknowledge that there are many previous publications suggesting 
that ANCA do activate neutrophils in vitro and encourage other 
investigators to re-examine this question.
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Figure 1 ANCA does not stimulate the neutrophil respiratory burst or degranulation in vitro. Ten control IgG, 11 MPO-ANCA and 9 PR3-ANCA 
were tested, with experiments performed in two neutrophil donors. The respiratory burst was assessed with (A) a dihydrorhodamine 123 assay of 
hydrogen peroxide generation, (B–C) luminol and isoluminol-based assays of total and extracellular superoxide generation. Degranulation products 
measured were (D) soluble MPO (azurophilic granules), (E) soluble lactoferrin (specific granules), (F) cell surface CD66b (specific granules) and (G) cell 
surface CD11b (secretory, gelatinase and specific granules). In (B–C), data shown are the peak response. For fMLP, this occurred at approximately 2 
min, whereas the peak response to IgG was at approximately 30 min. There were no significant differences between the groups for any of the assays. 
ANCA, antineutrophil cytoplasmic antibody; fMLP, N-formylmethionine-leucyl-phenylalanine; NA, not activated.
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